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1037Noninvasive Estimation of PA Pressure, Flow,
and Resistance With CMR ImagingOBJECTIVES The aim of this study was to develop a composite numerical model based on parameters from
cardiac magnetic resonance (CMR) imaging for noninvasive estimation of the key hemodynamic measurements
made at right heart catheterization (RHC).
BACKGROUND Diagnosis and assessment of disease severity in patients with pulmonary hypertension is
reliant on hemodynamic measurements at RHC. A robust noninvasive approach that can estimate key RHC mea-
surements is desirable.
METHODS A derivation cohort of 64 successive, unselected, treatment naive patients with suspected pulmo-
nary hypertension from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identiﬁed at a Referral
Centre) Registry, underwent RHC and CMR within 12 h. Predicted mean pulmonary arterial pressure (mPAP)
was derived using multivariate regression analysis of CMR measurements. The model was tested in an indepen-
dent prospective validation cohort of 64 patients with suspected pulmonary hypertension. Surrogate measures of
pulmonary capillary wedge pressure (PCWP) and cardiac output (CO) were estimated by left atrial volumetry and
pulmonary arterial phase contrast imaging, respectively. Noninvasive pulmonary vascular resistance (PVR) was
calculated from the CMR-derived measurements, deﬁned as: (CMR-predicted mPAP – CMR-predicted PCWP)/
CMR phase contrast CO.
RESULTS The following composite statistical model of mPAP was derived: CMR-predicted mPAP ¼ –4.6 þ
(interventricular septal angle  0.23) þ (ventricular mass index  16.3). In the validation cohort a strong correlation
between mPAP and MR estimated mPAP was demonstrated (R2 ¼ 0.67). For detection of the presence of
pulmonary hypertension the area under the receiver-operating characteristic (ROC) curve was 0.96 (0.92 to 1.00;
p < 0.0001). CMR-estimated PVR reliably identiﬁed invasive PVR $3 Wood units (WU) with a high degree of
accuracy, the area under the ROC curve was 0.94 (0.88 to 0.99; p < 0.0001).
CONCLUSIONS CMR imaging can accurately estimate mean pulmonary artery pressure in patients with sus-
pected pulmonary hypertension and calculate PVR by estimating all major pulmonary hemodynamic metrics
measured at RHC. (J Am Coll Cardiol Img 2013;6:1036–47) ª 2013 by the American College of Cardiology
Foundationulmonary hypertension (PH) is a condition
of varied etiology deﬁned by mean pulmo-
nary artery pressure (mPAP) $25 mm Hg
measured at right heart catheterization
(RHC) (1). Mild elevations of pulmonary artery
pressure are seen in the context of chronic respira-
tory and cardiac disease, whereas severe elevations of
pulmonary artery pressure are seen in pulmonary
arterial hypertension and chronic thromboembolic
PH where speciﬁc therapies are available.
In addition to making measures of mPAP, RHC
allows direct measurement of cardiac output (CO),
pulmonary capillary wedge pressure (PCWP) and
calculation of pulmonary vascular resistance (PVR),
which are key variables in diagnosis, risk stratiﬁca-
tion, and follow-up. CO is an invasively measured
variable that can be quantiﬁed noninvasively using anumber of techniques including cardiac magnetic
resonance (CMR) phase contrast imaging and car-
diac volumetric analysis (2,3). On the contrary, use of
CMR for estimation of mPAP, PCWP, and PVR
remains uncertain. Doppler echocardiography is
currently the modality of choice in clinical practice for
noninvasive assessment of patients with suspected
PH, however, the technique does not perform well
for some etiologies of PH (4,5), and there is a limited
role in patient follow-up.
RHC is the gold standard for establishing a
diagnosis of PH and changes in PVR are thought to
indicate the effectiveness of therapies for patients
with pulmonary arterial hypertension. In severe PH,
however, falls in mPAP may contribute to a fall in
PVR in the setting of worsening of right ventricular
(RV) function. Hence, some investigators consider
A B B R E V I A T I O N S
A N D A C R O N YM S
BSA = body surface area
CMR = cardiac magnetic
resonance
CO = cardiac output
LA = left atrial
LV = left ventricle/ventricu
mPAP = mean pulmonary
arterial pressure
PCWP = pulmonary capilla
wedge pressure
PH = pulmonary hypertens
PVR = pulmonary vascular
resistance
RHC = right heart catheteri
ROC = receiver-operating
characteristic
RV = right ventricular
SA = short axis
SSFP = steady-state free
precession
VMI = ventricular mass ind
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1038CMR and RHC to be complementary in the
assessment of patients with severe PH. An accurate
and reproducible noninvasive technique capable of
estimating pulmonary hemodynamic metrics in
addition to morphological and functional measures
of RV function would be highly desirable. Several
preliminary studies have shown signiﬁcant relation-
ships between CMRmetrics and invasively measured
mPAP (6–10) and PVR (11,12) in PH, though the
results of these studies were not validated in pro-
spective cohort studies. The aim of this study was to
derive and validate physiologically plausible com-
posite numerical models of mPAP and PVR from
CMR imaging parameters.lar
ry
ion
zation
exMETHODS
Patients. The cohort used for model
derivation included consecutive treatment
naive patients identiﬁed between July 2009
and March 2010 from the ASPIRE
(Assessing the Spectrum of Pulmonary
Hypertension Identiﬁed at a Referral
Centre) PH registry (13). Inclusion
required the patient to be referred with
suspected PH and have undergone same
day RHC and CMR imaging. Patients
were excluded if the imaging was of
nondiagnostic quality. Patients were clas-
siﬁed following complete diagnostic
work-up according to recent guidelines
(1), including standard blood testing,
echocardiography, lung function, exercise
testing and imaging investigations in-
cluding computerized tomography, perfu-
sion lung scanning, CMR, and RHC.
Ethical approval for retrospective review of
routinely performed investigations in the
derivation cohort was granted by the localinstitutional review board. Patients in the validation
cohort were recruited from the Shefﬁeld Pulmonary
Hypertension Biobank and gave written informed
consent to allow use of their prospectively collected
data.
Imaging. CMR imaging was performed on a 1.5-T
whole body scanner GE HDx (GE Healthcare,
Milwaukee, Wisconsin), using an 8-channel cardiac
coil with the patients supine. Four-chamber and
short axis (SA) cine images were acquired using a
retrospective cardiac gated multislice steady-state
free precession (SSFP) sequence. A stack of axial
images in the SA plane with slice thickness of 8 mm
with a 2 mm interslice gap or 10 mm with
no interslice gap were acquired fully covering bothventricles from base to apex. The SSFP sequence
parameters were repetition time (TR) 2.8 ms, echo
time (TE) 1.0 ms, ﬂip angle 50, ﬁeld of view 48 
43.2, 256  256 matrix, 125 kHz bandwidth, and
slice thickness of 8 to 10 mm.
Phase contrast ﬂow imaging was performed
with a compensated velocity encoded 2D gradient
echo sequence with parameters were TR 5.6 ms, TE
2.7 ms, slice thickness 10 mm, ﬁeld of view 48 
28.8, bandwidth 62.5 kHz, 256  128 matrix,
20 reconstructed cardiac phases, and velocity
encoding 150 cm/s. The plane of the phase contrast
imaging was orthogonal to the pulmonary arterial
trunk, 2 perpendicular SSFP planning slices were
acquired in the long axis of the pulmonary artery to
achieve the orthogonal position.
Image analysis. Image analysis was performed on a
GE Advantage Workstation 4.4 and GE Advantage
Workstation ReportCard, the observer was blinded
to the patient clinical information and cardiac
catheter parameters. Patient scans were deﬁned as
nondiagnostic when image quality signiﬁcantly
affected cardiac measurements or volumetric anal-
ysis could not be accurately performed. The CMR
parameters were corrected where appropriate for
body surface area (BSA), as previously reported in
the literature (14,15).
Volume and mass measurements. Left and right
endocardial surfaces were manually traced from the
stack of SA cine images to obtain end-diastolic
volume and end-systolic volumes, using MR work-
station software (GE Advantage Workstation
ReportCard). From end-diastolic and end-systolic
volumes, the left ventricular (LV) and RV ejection
fractions and right stroke volumes were calculated.
LV stroke volume was multiplied by heart rate to
determine CO. The RV epicardial and endocardial
borders on each end-diastolic SA slice image were
carefully outlined. The interventricular septum was
considered as part of the LV. The myocardial volume
for each slice was calculated by multiplying the area
of the RV wall by the slice thickness. The product
of the sum total of the myocardial slice volumes
for each ventricle and the density of myocardium
(1.05 g/cm3) gave an estimate of right ventricular
mass (RVmass) (6,8) (Fig. 1). The LV epicardial and
endocardial borders on each end-diastolic SA slice
were also outlined, LV end-diastolic mass was thus
derived. Ventricular mass index (VMI) was deﬁned
as RV mass divided by LV mass.
Phase contrast measurements. Phase contrast
Q-ﬂow CMR imaging was analyzed using Report-
Card software, and the contours of the vessel were
automatically traced, with manual correction when
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was recorded as the average from all pixels traced
from the vessel region of interest. Average pulmonary
arterial velocity (cm/s) was deﬁned as average pul-
monary arterial ﬂow divided by average pulmonary
arterial area. Maximal and minimal pulmonary
arterial areas were measured, and relative area change
was deﬁned by the following equation: (maximal
area – minimum area)/minimum area (10,15,16).
Interventricular septum. The interventricular septum
was assessed on the mid-chamber SA cine cardiac
images at the phase of maximal septal displacement.
Interventricular septal angle was measured by de-
termining the angle between the mid-point of the
interventricular septum and the 2 hinge points. The
angle between the 2 hinge points and the mid-point
of the LV free wall was also measured (Fig. 1).
Septal angle ratios were calculated from the ratio of
interventricular septal angle to free wall angle.
Left atrial volume. Left atrial (LA) volume was
estimated using the well-established biplane area
length method (17,18). LV long axis (2-chamber
view) and 4-chamber views were analyzed. LA
volume was calculated from the equation: (0.85 
LA area 2-chamber view  LA area 4-chamber
view)/([LA length 2-chamber þ LA length
4-chamber]/2) (19,20). The LA volume wasFigure 1. Interventricular Septal Angle and RV Mass Measurements
(A) The method for calculating interventricular septal angle, a, and left
ventricular (RV) volume measurement from a single short axis slice. RV vo
with the mass calculated from RV epicardial volume minus endocardia
calculated as RV mass divided by left ventricular mass.adjusted for body surface area (LA index) to esti-
mate PCWP.
RHC. RHC was performed using a balloon-tipped
7.5-F thermodilution catheter (Becton-Dickinson,
Franklin Lakes, New Jersey). PH was deﬁned as
mPAP $25 mm Hg at rest. Patients referred with
suspected PH who were found to have a mPAP <25
mm Hg were deﬁned as no PH. CO was measured
using the thermodilution technique. PVR was deter-
mined as follows: PVR ¼ (mPAP – PCWP)/CO.
Cardiac index (CI) was corrected for the patient’s
BSA: CI ¼ CO/BSA.
Statistics. The derivation cohort was used to build a
composite numerical parametric model of mPAP.
To satisfy the assumptions of the statistical model
each variable was tested for any nonlinear relation
between continuous independent variables and
mPAP. Scatter plots of CMR metrics versus mPAP
were constructed. Regression curve ﬁtting deter-
mined the best ﬁt relationship using linear,
quadratic, exponential, logarithmic, inverse-linear,
or power analysis. To achieve linearity, variable
transformations were performed where necessary.
Statistically signiﬁcant CMR variables at univariate
analysis were entered into a multiple linear regres-
sion model of mPAP. The CMR data from the
prospective validation cohort were used to test theventricular free wall angle given by b. (B) Measurement of right
lume measurements are made on each ventricular end-diastolic slice,
l volume multiplied by 1.05 to give g/cm2. Ventricular mass index is
Table 2. Correlations of CMR Measurements With mPAP
Measured at Right Heart Catheterization
Derivation Cohort
(n [ 64)
Correlations With mPAP
R2 p Value
RV EDV index, ml/m2 0.29 <0.0001
RV ESV index, ml/m2 0.23 <0.0001
RV ejection fraction, % 0.29 <0.0001
RV stroke volume index, ml/m2 0.11 0.008
RV mass index, g/cm5 0.60 <0.0001
Ventricular mass index (ratio) 0.66 <0.0001
LV EDV index, ml/m2 0.08 0.022
LV ESV index, ml/m2 0.03 0.181
LV ejection fraction, % 0.02 0.289
LV stroke volume index, ml/m2 0.16 0.001
Pulmonary artery RAC, % 0.49 <0.0001
Average PA velocity, cm/s 0.33 <0.0001
Interventricular septal angle,  0.67 <0.0001
Interventricular septal angle ratio 0.63 <0.0001
CMR ¼ cardiac magnetic resonance; EDV ¼ end-diastolic volume; ESV ¼ end-
systolic volume; LV ¼ left ventricular; PA ¼ pulmonary arterial; RAC ¼ relative
area change; RV ¼ right ventricular.
Table 1. Derivation and Validation Study Groups
Derivation
Cohort
(n [ 64)
Validation
Cohort
(n [ 64) p Value
Demographics
Age, yrs 62.9  13.5 62.8  12.8 0.986
Female, % 65.6 55.3 0.332
Subgroups
Group 1-PAH 23 29 0.286
Group 2-PH-LHD 9 5 0.421
Group 3-PH-RESP 10 7 0.604
Group 4-CTEPH 10 12 0.815
Multifactorial 0 1 d
No PH (mPAP <25 mm Hg) 12 10 0.815
RHC
mRAP, mm Hg 9.7  5.8 9.2  5.8 0.606
mPAP, mm Hg 37.4  14.7 41.1  13.6 0.140
PCWP, mm Hg 13.1  4.7 11.6  5.0 0.065
CO, l/min 5.8  1.8 5.4  1.7 0.134
CI, l/min/m2 3.2  0.9 2.9  0.9 0.101
PVR, WU 4.9  4.2 6.6  4.6 0.042
Values are mean  SD, %, or n.
CI ¼ cardiac index; CO ¼ cardiac output; CTEPH ¼ chronic thromboembolic pulmonary hypertension;
mPAP ¼ mean pulmonary arterial pressure; mRAP ¼ mean right atrial pressure; PAH ¼ pulmonary arterial
hypertension; PCWP ¼ pulmonary capillary wedge pressure; PH ¼ pulmonary hypertension; PH-LHD ¼
pulmonary hypertension owing to left heart disease; PH-RESP ¼ pulmonary hypertension associated
with respiratory disease; PVR ¼ pulmonary vascular resistance; RHC ¼ right heart catheterization; WU ¼
Woods Unit.
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1040CMR-predicted mPAP versus RHC measured
mPAP. Comparisons of CMR measurements be-
tween the derivation and validation cohorts
(Table 1) were analyzed using an independent t test
for continuous data, and the chi-square test for
categorical data.
CMR-measured LA volume index was considered
a surrogate marker of PCWP. This was based on
previous work showing that LA volume measure-
ments are reproducible (20) and have a reasonable
correlationwith PCWP (21). Noninvasive estimation
of PCWP was made using linear regression analysis
to determine the relationship between LA volume
and invasively measured PCWP. Transpulmonary
gradient was thus determined as follows: trans-
pulmonary gradient ¼ CMR-predicted mPAP –
CMR-estimated PCWP. CMR phase contrast
imaging has been well validated as a method of
estimating CO in humans (3). By dividing CMR-
estimated transpulmonary gradient (predicted
mPAP – predicted PCWP) by phase contrast CO, a
CMR-based PVR was derived, assuming the stan-
dard formula PVR ¼ mPAP – PCWP/CO.
Linear regression was used to assess the strength of
the relationships between invasive mPAP, PCWP,CO, and PVR and CMR-derived mPAP, PCWP,
CO, and PVR measurements. Bland-Altman anal-
ysis was used to assess the agreement between
CMR-derived hemodynamics parameters versus
invasively measured values (22). The bias, standard
deviation, and the 95% limits of agreement were
reported. Receiver operating characteristic (ROC)
curves were constructed to determine the diagnostic
accuracy of CMR-derived mPAP for the detection
of PH, and were used to test the diagnostic value
of CMR-predicted PVR for detection of PVR >3
WU. Diagnostic accuracy was quantiﬁed by the area
under the ROC curve. Area under the ROC curve
#0.5 indicates no value. The closer the area is to 1.0,
the greater the diagnostic utility and signiﬁcance of
the test. A p value <0.05 was considered statistically
signiﬁcant. To perform and display the statistics,
PASW 18 (PASW, Chicago, Illinois) and Graph-
Pad Prism 5.04 (GraphPad Software, San Diego,
California) software were used.RESULTS
Patients. A total of 69 patients were identiﬁed hav-
ing same-day RHC and CMR from the ASPIRE
registry (13), of whom 64 patients had diagnostic
quality imaging. A second cohort of 66 patients
were prospectively recruited, 2 of whom had non-
diagnostic imaging. Thus, 64 patients were included
E F
G H
Figure 2. Derivation Cohort
Scatter plots of cardiac magnetic resonance (CMR) versus invasive hemodynamic measurements for the derivation cohort: (A) composite CMR-
derived mean pulmonary arterial pressure versus right heart catheterization (RHC)–measured mPAP; (B) CMR-derived pulmonary capillary
wedge pressure (PCWP) versus PCWP measured at RHC; (C) CMR phase contrast measured cardiac output (CO) and CO measured by ther-
modilution; (D) noninvasive CMR estimated pulmonary vascular resistance (PVR) versus RHC-derived PVR. Bland-Altman plots showing the
level of agreement between (E) CMR-derived mPAP versus RHC-measured mPAP, (F) CMR PCWP versus RHC PCWP, (G) CMR phase contrast
CO versus CO by thermodilution, and (H) CMR-determined PVR and PVR measured at RHC. Dashed line ¼ bias; dotted lines ¼ upper and
lower limits of agreement.
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Figure 3. Validation Cohort
Scatter plots CMR versus invasive hemodynamic measurements for the prospective validation cohort: (A) composite CMR-derived mPAP
versus RHC-measured mPAP; (B) shows CMR-derived PCWP versus PCWP measured at RHC; (C) CMR phase contrast measured CO and CO
measured by thermodilution; and (D) noninvasive CMR estimated PVR versus RHC-derived PVR. Bland-Altman plots showing the level of
agreement between (E) CMR-derived mPAP versus RHC measured mPAP, (F) CMR PCWP versus RHC PCWP, (G) CMR phase contrast CO versus
CO by thermodilution, and (H) CMR-determined PVR and PVR measured at RHC. Abbreviations as in Figure 2.
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C D
Figure 4. Receiver-Operating Characteristic Curves Showing Diagnostic Accuracy
(A) CMR-derived mPAP to detect the presence of pulmonary hypertension, (B) CMR-derived PVR to identify patients with a PVR <3 Woods
units in the derivation cohort. Validation cohort results are displayed in (C) and (D). AUC ¼ area under the curve.
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1043in the validation cohort. Patient demographics and
hemodynamics are shown in Table 1.
Estimation of mPAP. Linearity of CMR metrics
versus mPAP was found with all tested variables
except for pulmonary artery relative area change for
which the best ﬁt relationship was exponential.
Table 2 presents the correlations between CMR var-
iables and invasively measured mPAP at RHC. The
multivariate linear regression model of best ﬁt iden-
tiﬁed the measurements interventricular septal angle
and VMI index. The parametric relationship was as
follows: MR-predicted mPAP ¼ –4.6 þ (interven-
tricular septal angle  0.23) þ (VMI  16.3).
In the derivation cohort, CMR-predicted mPAP
and invasive mPAP demonstrated a signiﬁcant
correlation (R2 ¼ 0.75, p < 0.0001) (Fig. 2). High
diagnostic accuracy for the identiﬁcation of PH wasidentiﬁed, area under the ROC curve was 0.94 (0.87
to 1.00; p < 0.0001).
The model of predicted mPAP correlated well
with invasive mPAP in the validation cohort (R2 ¼
0.67, p < 0.0001) (Fig. 3). For detection of the
presence of PH, the area under the ROC curve was
0.96 (0.92 to 1.00; p < 0.0001), and predicted
mPAP of $32 mm Hg was identiﬁed as the most
favorable threshold with 87% sensitivity and 90%
speciﬁcity (Fig. 4).
Intraobserver and interobserver agreement were
measured in 20 randomly selected patients. There
was good intraobserver agreement intraclass corre-
lation coefﬁcient 0.99 (0.97 to 2.00) and Bland-
Altman analysis showed a bias of 1.1  6.3 with
95% limits of agreement of –11.3 to 13.4. Good
interobserver agreement was also shown intraclass
Table 3. Bland-Altma
of Agreement for CM
CMR-Derived Hemo
CMR mean pulmonary
Derivation cohort
Validation cohort
CMR pulmonary capil
Hg
Derivation cohort
Validation cohort
CMR cardiac output, l
Derivation cohort
Validation cohort
CMR pulmonary vascu
Derivation cohort
Validation cohort
CMR ¼ cardiac magnetic
Swift et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 1 0 , 2 0 1 3
CMR Estimation of RHC Hemodynamic O C T O B E R 2 0 1 3 : 1 0 3 6 – 4 7
1044correlation coefﬁcient 0.97 (0.91 to 0.99) and
Bland-Altman analysis showed a bias of 1.3  6.9
and limits of agreement of –12.2 to 14.9.
Phase contrast CO. LV SSFP and phase contrast
CMRboth correlatedmoderately withCOmeasured
by thermodilution (R2¼ 0.46 and 0.49, respectively,
in the derivation cohort). When directly compared
phase contrast CMR and LV SSFP also had a
moderate correlation (R2 ¼ 0.49). The correlation
between CO estimated by thermodilution and phase
contrast CMR was signiﬁcant (R2 ¼ 0.44, p <
0.0001) in the validation cohort. Bland-Altman
agreement analysis results for CMR-derived hemo-
dynamic including CO are presented in Table 3.
Estimation of PCWP. The regression equation of
estimated PCWP from the derivation cohort was as
follows: CMR-derived PCWP¼ 6.43þ LA volume
index  0.22. In the retrospective and prospective
validation cohorts, modest correlations (R2 ¼ 0.36
and 0.49, respectively) were found between invasively
measured PCWP at RHC and CMR-estimated
PCWP. See Table 3 for Bland-Altman agreement
analysis results. For the noninvasive detection of
elevated PCWP ($15 mm Hg) in the validation
cohort, the area under the ROC curve for the detec-
tion of elevated PCWP was 0.90 (0.78 to 1.00;
p < 0.0001) with an optimal threshold value of
$15mmHg identiﬁed as the optimal cutoff threshold
with sensitivity of 85% and speciﬁcity of 94%.
PVR. Noninvasive CMR- and RHC-derived PVR
correlated well in the derivation and validationn Analysis Data Presenting Bias, Standard Deviation, and Limits
R-Derived Hemodynamic Measurements
dynamic Measurements
Bland-Altman Agreement Results
Bias SD
Limits of
Agreement
artery pressure, mm Hg
0.05 7.16 13.9 to 14.1
0.50 7.70 15.7 to 14.7
lary wedge pressure, mm
0.0003 3.80 7.4 to 7.4
1.70 3.60 5.4 to 8.7
/min
0.40 1.20 1.9 to 2.8
0.155 1.30 2.5 to 2.8
lar resistance, WU
0.25 2.50 5.1 to 4.6
0.54 2.30 4.0 to 5.1
resonance; WU ¼ Woods Unit.cohorts (R2 ¼ 0.67, p < 0.0001; R2 ¼ 0.76, p <
0.0001, respectively). See Table 3 for Bland-Altman
agreement analysis results. For detection of elevated
PVR ($3 WU at RHC) in the derivation cohort the
area under the ROC was 0.95 (0.90 to 1.00; p <
0.0001). For detection of elevated PVR in the
validation cohort the area under the ROC remained
high at 0.94 (0.88 to 0.99; p < 0.0001).
D I SCUSS ION
This study has derived, for the ﬁrst time, a CMR
noninvasive composite parametric regression model
for mPAP and demonstrated that it has good diag-
nostic accuracy when used prospectively in a hetero-
geneous cohort of patients with suspected PH. In
addition, we have shown that PVR can be predicted
using CMR estimates of mPAP, CO, and PCWP
and that this prediction also has high diagnostic ac-
curacy. These results demonstrate that invasively
measured variables, traditionally made at RHC, that
are crucial for clinical evaluation of patients with PH
(pressure, vascular resistance, and ﬂow) can be non-
invasively estimated using CMR imaging in this pa-
tient cohort. Importantly, CMR is noninvasive,
reproducible (23,24), sensitive to change (25–27), and
does not require ionizing radiation, making it an ideal
modality for ongoing assessment of patients with PH.
In current clinical practice echocardiography is
used as the ﬁrst line investigation for suspected
PH, allowing assessment of RV morphology and
function and estimation of pulmonary arterial
pressure. Using the modiﬁed Bernoulli equation
the pressure gradient between the right ventricle
and right atrium based on the velocity of the
tricuspid regurgitant jet can be calculated. Esti-
mated right atrial pressure is added to this equation
to predict pulmonary artery systolic pressure (28)
and a number of studies have subsequently
used this measure to estimate mPAP. Several studies
have identiﬁed a strong relationship between
echocardiographic measures of mPAP made at
RHC (29,30). However, the diagnostic utility of
echocardiography-derived mPAP has been ques-
tioned in speciﬁc underlying etiologies (4). More-
over, a recent prospective study of unselected patients
with PH, has shown the under and over estimation
of Doppler echocardiography-derived mPAP with
limits of agreement ranging from –40 to 38.8mmHg
(28). Concerns regarding the reproducibility of
echocardiographic measures have been expressed
and challenges exist in accurate delineation
of RV morphological features. Consequently, echo-
cardiography has not yet been adopted as a stand-
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hemodynamic metrics and RV morphology and
function. RHC has been advocated as the gold
standard to assess the response to treatment when
results of noninvasive assessments such as clinical
assessment, 6-min walking test and echocardiogra-
phy have been equivocal. Concerns regarding falls in
PVR measured at RHC in the setting of worsening
right ventricular function have resulted in some
physicians advocating an approach based on using
both RHC and MR metrics.
Several studies have identiﬁed signiﬁcant re-
lationships, between CMR imaging metrics and
mPAP (6,8–10,31–35) and PVR (11,36,37) in
patients with PH. However, this is the ﬁrst study
to devise a CMR-based prediction model for
estimation of mPAP and to validate the results
prospectively. The numerical linear regression
model, a composite index of VMI (the ratio of
RV:LV mass) and interventricular septal angle
correlated well with mPAP in the derivation and
prospective validation cohorts and showed good
diagnostic utility. This model includes 2 variables
namely, VMI and the degree of septal curvature,
that are physiologically linked to pulmonary artery
pressure in addition to having a strong statistical
relationship. VMI has been shown in previous
work by other investigators to correlate strongly
with mean pulmonary arterial pressure, likewise
septal curvature has been shown to relate well to
pulmonary arterial pressure (6,31). This study de-
scribes a novel, simple, and reproducible method of
evaluating septal curvature based on the angle of
the septum in relation to the 2 septal hinge
points, a similar correlation between septal angle
verses mPAP in comparison to septal curvature
versus mPAP from previous work was found
(7,38). We also sought to estimate PCWP in order
to replicate the key measurements made at RHC,
which would also allow a noninvasive estimation
of PVR. LA size adjusted for BSA was used as a
plausible physiological correlate and demonstrated
a moderate correlation with invasively measured
PCWP. Further study of CMR measures to try
and improve estimation of LA pressure, estimated
at RHC by PCWP, such as transmitral ﬂow
measurements with the addition of septal tissue
velocity, may be of value for improved estimation of
LA pressure.
A recent study (36) used a derivation and valida-
tion cohort to devise and test a noninvasive CMR
model of PVR. The study identiﬁed a prediction rule
based on RV ejection fraction and the natural logof average pulmonary arterial velocity, the model
performed well in the validation cohort. The limits
of agreement at Bland-Altman analysis were –6.0 to
4.9 WU, and area under the ROC curve analysis for
the diagnosis of PH was 0.97. Our study derives a
prediction rule for mPAP based on physiological
measurements, an estimate of PCWP based on LA
volume and phase contrast CMR CO (39,40) to
derive PVR. In comparison, narrower limits of
agreement were found in the present study at Bland-
Altman analysis, –5.1 to 4.6 WU. Additionally,
CMR-derived PVR was found to have a high degree
of accuracy for predicting raised PVR as measured by
catheterization (area under the ROC curve: 0.94),
while diagnostic accuracy for PH was also strong
(area under the ROC curve: 0.96).
Study limitations. Using multivariate linear regres-
sion analysis, a parametric model, to derive an
equation to ﬁt a physiological process inherently has
its limitations, as the models are not physically
founded. However, the variables identiﬁed by the
multivariate model VMI and interventricular septal
position have been shown in previous work to be
strong consistent markers of mPAP (6,7,34).
Furthermore RHC, estimation of PVR is made
with the variables PCWP, mPAP, and CO, using
the equation: PVR ¼ (mPAP – PCWP)/CO.
PCWP measurements can be inaccurate in esti-
mating LV end-diastolic pressure. Ideally a CMR
surrogate of LV end-diastolic pressure measured at
left heart catheterization would be superior to a
surrogate of PCWP. Further study assessing the
correlation between LA CMR measurements and
LV pressures is required. Estimates of CO using
CMR have been shown to have moderate correla-
tion with invasive measurements (3), however,
phase contrast measurements may be affected by
turbulent ﬂow, which may result in inaccuracies in
this measurement. Finally it is also necessary to
consider the logistic and ﬁnancial issues associated
with implementation of CMR in the assessment of
patients with PH, such as cost, availability, and
expertise.
Clinical implications. This study demonstrates the
feasibility of CMR to estimate key pulmonary
hemodyamic measurements in addition to
morphological and functional RV measurements,
making this an ideal noninvasive modality for the
assessment and follow-up of patients with PH. In
clinical practice follow-up CMR may reduce the
need for repeat RHC by providing the physician
with an estimate of hemodynamic parameters pre-
viously only conﬁdently measured at cardiac
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1046catheterization, in addition to CMR prognostic
indexes (14).
CONCLUS IONS
CMR imaging, in addition to providing detailed
functional and morphological information, can
accurately estimate mean pulmonary artery pressurein patients with PH and calculate PVR by esti-
mating all major pulmonary hemodynamic metrics
measured at RHC.
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